Connor, Clark & Lunn Investment Management (CC&L)’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $22.2M | Sell |
403,547
-117,802
| -23% | -$6.48M | 0.08% | 230 |
|
|
2025
Q1 | $36.9M | Buy |
521,349
+164,853
| +46% | +$11.7M | 0.16% | 108 |
|
|
2024
Q4 | $23.4M | Buy |
356,496
+240,239
| +207% | +$15.8M | 0.11% | 150 |
|
|
2024
Q3 | $8.17M | Buy |
+116,257
| New | +$8.17M | 0.04% | 324 |
|
|
2023
Q4 | – | Sell |
-5,292
| Closed | -$468K | – | 1387 |
|
|
2023
Q3 | $468K | Sell |
5,292
-9,060
| -63% | -$802K | ﹤0.01% | 1031 |
|
|
2023
Q2 | $1.24M | Sell |
14,352
-216,114
| -94% | -$18.7M | 0.01% | 735 |
|
|
2023
Q1 | $22.4M | Sell |
230,466
-87,430
| -28% | -$8.5M | 0.12% | 145 |
|
|
2022
Q4 | $32.9M | Buy |
317,896
+116,511
| +58% | +$12.1M | 0.19% | 89 |
|
|
2022
Q3 | $17.1M | Sell |
201,385
-45,816
| -19% | -$3.88M | 0.11% | 140 |
|
|
2022
Q2 | $20.5M | Buy |
247,201
+91,298
| +59% | +$7.57M | 0.12% | 130 |
|
|
2022
Q1 | $12M | Buy |
155,903
+142,606
| +1,072% | +$11M | 0.06% | 202 |
|
|
2021
Q4 | $1.18M | Sell |
13,297
-58,034
| -81% | -$5.13M | 0.01% | 651 |
|
|
2021
Q3 | $5.51M | Buy |
71,331
+50,623
| +244% | +$3.91M | 0.03% | 318 |
|
|
2021
Q2 | $1.73M | Buy |
20,708
+12,910
| +166% | +$1.08M | 0.01% | 575 |
|
|
2021
Q1 | $589K | Sell |
7,798
-17,594
| -69% | -$1.33M | ﹤0.01% | 771 |
|
|
2020
Q4 | $2.23M | Buy |
25,392
+16,284
| +179% | +$1.43M | 0.01% | 487 |
|
|
2020
Q3 | $693K | Buy |
9,108
+1,387
| +18% | +$106K | ﹤0.01% | 686 |
|
|
2020
Q2 | $952K | Buy |
+7,721
| New | +$952K | 0.01% | 626 |
|
|
2020
Q1 | – | Sell |
-8,800
| Closed | -$744K | – | 1022 |
|
|
2019
Q4 | $744K | Buy |
8,800
+625
| +8% | +$52.8K | 0.01% | 596 |
|
|
2019
Q3 | $551K | Buy |
8,175
+2,875
| +54% | +$194K | ﹤0.01% | 663 |
|
|
2019
Q2 | $454K | Buy |
+5,300
| New | +$454K | ﹤0.01% | 741 |
|
|
2018
Q2 | – | Sell |
-6,300
| Closed | -$511K | – | 1035 |
|
|
2018
Q1 | $511K | Sell |
6,300
-700
| -10% | -$56.8K | ﹤0.01% | 569 |
|
|
2017
Q4 | $624K | Sell |
7,000
-12,275
| -64% | -$1.09M | ﹤0.01% | 591 |
|
|
2017
Q3 | $1.79M | Buy |
19,275
+16,575
| +614% | +$1.54M | 0.01% | 441 |
|
|
2017
Q2 | $245K | Buy |
+2,700
| New | +$245K | ﹤0.01% | 710 |
|
|
2016
Q3 | – | Sell |
-6,600
| Closed | -$513K | – | 840 |
|
|
2016
Q2 | $513K | Sell |
6,600
-11,900
| -64% | -$925K | ﹤0.01% | 580 |
|
|
2016
Q1 | $1.53M | Buy |
+18,500
| New | +$1.53M | 0.01% | 379 |
|
|
2015
Q4 | – | Sell |
-4,900
| Closed | -$516K | – | 814 |
|
|
2015
Q3 | $516K | Buy |
+4,900
| New | +$516K | ﹤0.01% | 516 |
|
|
2014
Q1 | – | Sell |
-5,830
| Closed | -$436K | – | 683 |
|
|
2013
Q4 | $436K | Buy |
+5,830
| New | +$436K | ﹤0.01% | 523 |
|